Herr H W, Engen D E, Hostetler J
J Urol. 1979 May;121(5):584-6. doi: 10.1016/s0022-5347(17)56889-5.
The incidence of cancer was compared in 499 dialysis patients and 121 renal transplant recipients. De novo malignancy developed in 15 patients on chronic dialysis (3 per cent) and in 6 transplant recipients (4.9 per cent), a significant increase over the expected number in the age-matched general population. There was no difference in the incidence of cancer in uremic patients on dialysis or after transplantation. A total of 10 dialysis patients (67 per cent) and 1 transplant patient (16 per cent) died of cancer. Neoplasms in the dialysis patients were the common types of mesenchymal tumors, while superficial skin cancers were seen more frequently in the transplant recipients. The differences in tumor types accounted for the higher mortality rate from cancer in the dialysis patients and may reflect different patterns of immunosuppression in these 2 patient populations.
对499名透析患者和121名肾移植受者的癌症发病率进行了比较。15名长期透析患者(3%)和6名移植受者(4.9%)发生了新发恶性肿瘤,这一数字显著高于年龄匹配的普通人群的预期数量。透析的尿毒症患者或移植后的患者癌症发病率没有差异。共有10名透析患者(67%)和1名移植患者(16%)死于癌症。透析患者的肿瘤为常见的间叶组织肿瘤类型,而移植受者中浅表皮肤癌更为常见。肿瘤类型的差异导致透析患者的癌症死亡率更高,这可能反映了这两类患者群体不同的免疫抑制模式。